The immunoglobulin heavy-chain gene 3′ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells

Oncogene

Volumn 26, Issue 18, 2007, Pages 2635-2641

  Duan, H ^a   Heckman, C A ^a   Boxer, L M ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bcl 2; Follicular lymphoma; IgH enhancer; Promoter usage

Indexed keywords

BINDING PROTEIN; ENHANCER BINDING PROTEIN BETA; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ALLELE; ANIMAL CELL; ARTICLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DEREGULATION; ENHANCER REGION; EPISOME; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; IN VIVO STUDY; LYMPHOMA CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS;

ACETYLATION; ANIMALS; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HISTONES; HUMANS; LYMPHOMA; MICE; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

MURINAE;

EID: 34247362486     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210061     Document Type: Article

References (19)

1. Cleary ML, Smith SD, Sklar J. (1986). Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47: 19-28.
2. Decary S, Decesse JT, Ogryzko V, Reed JC, Naguibneva I, Harel-Bellan A et al. (2002). The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2. Mol Cell Biol 22: 7877-7888.
3. Desoize B. (1994). Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294.
4. Duan H, Heckman CA, Boxer LM. (2005). HDAC inhibitors down-regulate Bcl-2 expression and induce apoptosis in t(14;18) lymphoma cells. Mol Cell Biol 25: 1608-1619.
5. Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang C et al. (2003a). Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 63: 6666-6673.
6. Heckman CA, Mehew JW, Boxer LM. (2002). NF-κB activates bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908.
7. Heckman CA, Wheeler MA, Boxer LM. (2003b). Regulation of bcl-2 by C/EBP in t(14;18) lymphoma cells. Oncogene 22: 7891-7899.
8. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336.
9. Ji L, Mochon E, Arcinas M, Boxer LM. (1996). CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas. J Biol Chem 271: 22687-22691.
10. Khamlichi AA, Pinaud E, Decourt C, Chauveau C, Cogne M. (2000). The 3' regulatory region: a complex structure in a search for a function. Adv Immunol 75: 317-345.
11. Krumm A, Hickey LB, Groudine M. (1995). Promoterproximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes Dev 9: 559-572.
12. Krumm A, Madisen L, Yang XJ, Goodman R, Nakatani Y, Groudine M. (1998). Long-distance transcriptional enhancement by the histone acetyltransferase PCAF. Proc Natl Acad Sci USA 95: 13501-13506.
13. Madisen L, Groudine M. (1994). Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev 8: 2212-2226.
14. Madisen L, Krumm A, Hebber TR, Groudine M. (1998). The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Mol Cell Biol 18: 6281-6292.
15. Reed JC, Kitada S, Takayama S, Miyashita T. (1994). Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5(Suppl 1): S61-S65.
16. Schmitt CA, Lowe SW. (2001). Bcl-2 mediates chemoresistance in matched pairs of primary Eμ-myc lymphomas in vivo. Blood Cells Mol Dis 27: 206-216.
17. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P et al. (1988). Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J 7: 123-131.
18. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. (1985). The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393.
19. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. (2001). Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20: 240-251.